Johnson & Johnson (JNJ) Interest Coverage Ratio: 26.36x
The interest coverage ratio for Johnson & Johnson (JNJ) is 26.36x as of Tuesday, June 9, 2026.
JNJ Interest Coverage Ratio Metrics
INTEREST COVERAGE RATIO
26.36x
JNJ Competitors' Interest Coverage Ratio
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Johnson & Johnson (JNJ) | — | 26.36x | N/A | N/A | N/A |
| Pfizer Inc. (PFE) | $146.48B | 5.78x | 5.55x | 10.96x | 11.04x |
| Merck & Co., Inc. (MRK) | $295.39B | 17.31x | 16.61x | 13.70x | 12.98x |
| AbbVie Inc. (ABBV) | $398.27B | 6.94x | 5.10x | 6.01x | 6.01x |
| Eli Lilly and Company (LLY) | $1.08T | 37.34x | 29.88x | 27.02x | 25.24x |
| Bristol-Myers Squibb Company (BMY) | $115.34B | 8.41x | 6.69x | 7.04x | 6.41x |
Financial Health Indicators
Interest Coverage
26.4x
Debt/Equity
0.59
Current Ratio
1.03
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
- < 1.5x: EBIT is less than 1.5 times interest expense
- 1.5x - 3x: EBIT is between 1.5 and 3 times interest expense
- 3x - 5x: EBIT is between 3 and 5 times interest expense
- > 5x: EBIT is more than 5 times interest expense
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Johnson & Johnson Interest Coverage Ratio Formula & Definition
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Johnson & Johnson Interest Coverage Ratio FAQ
- What is the interest coverage ratio for Johnson & Johnson (JNJ)?
- The interest coverage ratio for JNJ stock is 26.36x.
About Johnson & Johnson
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato